US-based healthcare company Welgistics Health has announced plans to use XRP not only as an investment vehicle but also as a payment instrument and profit-generating mechanism. Documents filed with the US Securities and Exchange Commission (SEC) by the company indicate that XRP has been integrated into its business model. Ripple advocate and attorney Bill Morgan commented on the SEC document, saying, “This S-1 filing lays out a strategy to integrate XRP not just as an asset but into the company's financial and operational structure.” According to Morgan, Welgistics Health aims to utilize the XRP Ledger infrastructure to process transactions with pharmacy customers and manufacturing and distribution partners in a cost-effective and real-time manner. This initiative is cited as an example of the real-world use of XRP in business-to-business payments. Related News: Critical Levels in Bitcoin Have Been Set - What Levels Must Be Exceeded for an Explosive Uptrend? What Level Is Important to Prevent a Decline? The same document also outlines the company's plans to raise funds through the issuance of stock or bonds in the future and use these funds to purchase additional XRP. The company intends to use the acquired XRP as collateral to raise funds and profit from XRP-based transactions. Bill Morgan commented on this as “an example of how XRP can go beyond being a mere investment vehicle and function as a means of payment and collateral.” However, these statements have sparked mixed reactions within the cryptocurrency community. While XRP supporters see the initiative as a positive use case, some experts have expressed skepticism about the company's financial structure. Former securities attorney Mark Fagel pointed out that Welgistics Health's actual assets are limited and that its recent financial reports include a “continue operating” warning. There has also been criticism that XRP could be used as a marketing tool. *This is not investment advice. Continue Reading: Nasdaq-Listed Company Announces XRP Reserve – But Doubts Remain
